非小细胞肺癌的CYFRA21-1、CA125与CEA联合检测的临床意义

Clinical Significance of Combined Detection of CYFRA21-1, CA125 and CEA for Patients with Non-small Cell Lung Cancer

探讨联合检测CYFRA2 1- 1、CA12 5、CEA对非小细胞肺癌的临床应用价值。1995年 8月至 2 0 0 0年 8月由病理证实的非小细胞肺癌患者 16 5例 ,同时测定血清CYFRA2 1- 1、CA12 5、CEA值。CYFRA2 1- 1在鳞癌中阳性率最高为 5 4 .5 5 % (30 / 5 5 ) ;CA12 5、CEA在腺癌中阳性率最高 ,分别为 5 8.5 9% (5 8/ 99)、5 2 .5 3% (5 2 / 99)。三项联检总阳性率明显升高为 81.82 % (135 / 16 5 ) ,其中Ⅲ期和Ⅳ期非小细胞肺癌的阳性检出率分别为 89.13% (41/ 4 6 )、86 .5 2 % (77/ 89) ,均高于Ⅰ期和Ⅱ期的阳性检出率。结论 :联合检测CYFRA2 1- 1、CA12 5和CEA可起到互补作用 ,从而明显提高非小细胞肺癌的阳性检出率 ,且肿瘤的阳性检出率随病情的进展而升高。

patients with pathologically proven non-small cell lung cancer(NSCLC) entered this study were analyzed by detecting the level of CYFRA21-1,CA125 and CEA in their serum during the period from August 1995 to August 2000 to investigate further clinical significance of combined detection of CYFRA21-1, CA125 and CEA for patients with NSCLC. Result: In different types of NSCLC, the highest positive rate of CYFRA21-1, 54.55%(30/55), is found to exist in the patients with squamous carcinoma, while the highest detected rates of both CA125 and CEA appear in the patients with adenocarcinoma. It is suggested in our study that the rate of positive findings may be raised by using combined detection of these three markers, because the rate of positive findings in the combined detection is 81.82(45/55), obviously higher than that for detection of any single marker. The rates of positive findings of NSCLC for the patients with stage Ⅲ and Ⅳ are 89.13%(41/46) and 86.52%(77/89), respectively, higher than 38.46%(5/13) of stage I and 58.82 %(10/17) of stage Ⅱ. Conclusion: It is showed in our study that combined detection of CYFRA21-1, CA125 and CEA may play a complementary role compared with detection of every single marker of them each other, and consequently evidently improves the rate of positive findings of NSCLC. Besides, the rate of positive findings increases along with development of the disease.